Pharmacological study of broperamole, a chemical novel antiinflammatory compound

N-3[5'-(3"-Bromophenyl)-2'H-tetrazole]propionyl piperidine (broperamole) was shown to elicit potent antiinflammatory activity following systemic administration to rats in acute and subchronic studies. The compound demonstrated systemic antiinflammatory activity 5-6 times that of phenylbutazone. Toical antiinflammatory activity was also demonstrated which was less than that of hydrocortisone but still should have clinical utility. Antipyretic activity, without effect on normal body temperature, was observed. Analgesic activity was not evidenced. Only at very high doses was gastric irritation noted; therefore, at anticipated human dose level, gastrointestinal toxicity in man should not occur.